|
| | NUCIFERINE Basic information | | Uses |
| Product Name: | NUCIFERINE | | Synonyms: | (-)-nucipherine;(r)-1,2-dimethoxyaporphine;1,2-dimethoxy-6a-beta-aporphin;6a;4H-Dibenzo[de,g]quinoline,5,6,6a,7-tetrahydro-1,2-diMethoxy-6-Methyl-, (6aR)-;Nuciferine
1,2-Dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline;satis indigotica fort Extract;Lotus Leaf Extract Nuciferin | | CAS: | 475-83-2 | | MF: | C19H21NO2 | | MW: | 295.38 | | EINECS: | | | Product Categories: | standardized herbal extract;chemical reagent;Miscellaneous Natural Products;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM). | | Mol File: | 475-83-2.mol |  |
| | NUCIFERINE Chemical Properties |
| Melting point | 165.5°C | | Boiling point | 437.06°C (rough estimate) | | density | 1.1156 (rough estimate) | | refractive index | 1.5000 (estimate) | | storage temp. | 2-8°C | | solubility | DMSO : 11.11 mg/mL (37.61 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble) | | form | powder | | pka | 7.87±0.20(Predicted) | | color | white to beige | | optical activity | [α]/D -145 to -165°, c = 0.5 in ethanol | | LogP | 2.357 (est) |
| Safety Statements | 24/25 | | RIDADR | UN 1544PSN1 6.1 / PGIII | | HS Code | 29389090 | | Toxicity | LD50 orl-rat: 280 mg/kg AIPTAK 197,261,72 |
| | NUCIFERINE Usage And Synthesis |
| Uses | The lotus leaf alkaloid has the effect of weight loss and lipid reduction, and can be used for content determination/identification/pharmacological experiments.
| | Description | Nuciferine is an aporphine alkaloid from Nelumbo lutea, the ba~e yields colourless crystals
when crystallized from EtOH. It is laevorotatory, the following specific rotations
having been recorded; [α] 22D- 157.5° and - 215°. The ultraviolet spectrum has
three absorption maxima at 230, 272 and 310 mp. Two methoxyl groups and
one methylimino group are present and the alkaloid may be characterized as the
hydrochloride, m.p. 241°C (in vacuo) and the methiodide, m.p. 177-8°C. The
optically inactive base has been synthesized and has m.p. 136-7°C, giving a
hydrochloride in the form of small colourless prisms from H20, m.p. 258°C
(dec.). | | Uses | Nuciferin is an drug candidate for the treatment of obesity-related diseases. It is not well studied and its pharmacokinetics in vivo have not been fully investigated. | | Safety Profile | Poison by ingestion andintraperitoneal routes. When heated to decomposition itemits toxic fumes of NOx. | | References | Gulland, Haworth., J. Chern. Soc., 590 (1928)
Yunusov, Konovalova, Orekhov., Bull. Soc. Chim. Fr., 70 (1940)
Arthur, Cheung., J. Chern. Soc., 2306 (1959)
Kupchan et al., Tetrahedron, 19, 227 (1963) |
| | NUCIFERINE Preparation Products And Raw materials |
|
